Day: January 3, 2024

Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”). The Company also expects to grant the initial purchaser in the offering an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $30.0 million aggregate principal amount of the Notes. The Notes will be senior unsecured obligations of the Company, are expected to pay interest semiannually and will mature on January 15, 2029, unless earlier purchased or converted in accordance...

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) — Teck Resources Limited (“Teck”), (TSX: TECK.A and TECK.B, NYSE: TECK) today announced the closing of the sale of a minority interest in its steelmaking coal business, Elk Valley Resources (“EVR”), to Nippon Steel Corporation (“NSC”) and POSCO. NSC has acquired a 20% interest in EVR in exchange for its prior 2.5% interest in Elkview Operations plus US$1.3 billion in cash paid at closing to Teck and US$0.4 billion paid subsequently to Teck out of cash flows from EVR. POSCO has exchanged its 2.5% interest in Elkview Operations and its 20% interest in the Greenhills joint venture, for a 3% interest in EVR. Closing of the sale of the remaining interest (77%) in EVR to Glencore PLC is expected to occur in the third quarter of 2024, subject to the satisfaction of customary...

PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8 at 8:15 am PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative...

Hong Kong, Jan. 03, 2024 (GLOBE NEWSWIRE) — Fenbo Holdings Limited (the “Company” or “Fenbo”), an established provider of personal care electric appliances and toys products to overseas markets, today announced the appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director, effective on January 1, 2024. Mr. Meng has over 20 years of experience in enterprise management, particularly in operational management of supply chain systems. He has accumulated rich knowledge and practical experience in areas such as corporate strategic planning, organizational management, integrated marketing, brand building, and upstream and downstream product development. Mr. Meng also possesses excellent skills in work communication, negotiation, business development, and public relations. He has practical experience in areas...

THE WOODLANDS, Texas, Jan. 03, 2024 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today that it will release its fourth quarter and full year 2023 operating results on Monday, February 5, 2024, after the market closes. The Company has scheduled a conference call for Tuesday, February 6, 2024, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to discuss the results. The call will be available by live webcast on ChampionX’s website at https://investors.championx.com or by dialing in as follows:United States:International:Reference:            1-888-259-65801-416-764-8624ChampionX conference call ID: 83686329Please register for the webcast or dial into the call approximately 15 minutes prior to the scheduled start time. A replay of the conference call will be available for 30...

CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 pm PT. The presentation will be webcast and an archived recording will be available for replay in the Investors section of the Madrigal website after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a liver-directed THR-β agonist oral therapy that is...

– On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 – – Extends projected cash runway into second half of 2025 – – Company to present at J.P. Morgan Healthcare Conference on January 11, 2024 at 7:30 a.m. PT/10:30 a.m. ET – WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today provided a 2023 year-in-review and outlined key milestones anticipated in 2024. The Company also today announced that it has extended its projected cash runway into the second half of 2025. “2023 marked a year of persistent...

MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that yesterday its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from January 3, 2024 to February 3, 2024 (the “Extension”). The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding. This is the third of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023. The Extension provides...

MELBOURNE, Australia, Jan. 03, 2024 (GLOBE NEWSWIRE) —  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (US). The presentation will take place on Tuesday 9 January at 3:00pm PST (6:00pm EST / 10:00am AEDT, 10 January). Participants can register for the webcast at the following link. The webcast will be accessible on demand on the Telix website following the event. To schedule a 1×1 meeting with Telix management, please contact 1×1@jpmorgan.com. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical...